(Q38460209)

3 September 2017

1 reference

title

Next generation prophylactic human papillomavirus vaccines (English)

1 reference

3 September 2017

John T Schiller

1

1 reference

PubMed ID

25943066

3 September 2017

Martin Müller

series ordinal

2

1 reference

3 September 2017

1 May 2015

1 reference

Lancet Oncology Commission

3 September 2017

1 reference

3 September 2017

16

1 reference

3 September 2017

5

1 reference

3 September 2017

e217-25

1 reference

Human papillomavirus vaccines--immune responses

3 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Understanding and learning from the success of prophylactic human papillomavirus vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

A review of clinical trials of human papillomavirus prophylactic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Safety of human papillomavirus vaccines: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

GAVI injects new life into HPV vaccine rollout

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Long-term persistence of human papillomavirus in environments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Systematic review of human papillomavirus vaccine coadministration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

HPV vaccine works against nine viral types

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Chapter 11: HPV vaccines: commercial research & development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Human papillomavirus vaccines in plants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

In vivo mechanisms of vaccine-induced protection against HPV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Optimization of multimeric human papillomavirus L2 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Mechanisms that determine plasma cell lifespan and the duration of humoral immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Influence of oxidation and multimerization on the immunogenicity of a thioredoxin-l2 prophylactic papillomavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Emerging human papillomavirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Human papillomavirus-specific immune therapy: failure and hope

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Chimeric papillomavirus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Does India need an indigenous HPV vaccine and why?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971179-9

7 January 2021

10.1016/S1470-2045(14)71179-9

Identifiers

DOI

1 reference

release_ap7f6ktxm5ea3lwrvg7ioj6hve

3 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ap7f6ktxm5ea3lwrvg7ioj6hve

24 November 2022

mapped directly with Wikidata item

PubMed ID

25943066

1 reference

PubMed ID

25943066